Table 5.

The league table for SAE estimates interventions according to their relative effects in first part network analysis

Apatoren+Taxane (49.6%)#
−0.21 (−2.02,1.61)	Icrucumab+Taxane (38.5%)
−0.25 (−2.00,1.51)	− 0.04 (− 1.85,1.77)	Pazopanib (36.7%)
0.18 (−1.36,1.73)	0.39 (−0.98,1.76)	0.43 (−1.11,1.97)	Ramucirumab+Taxane (59.7%)
0.47 (−0.77,1.71)	0.68 (−0.64,2.00)	0.72 (− 0.52,1.96)	0.29 (− 0.63,1.21)	Taxane (79.8%)
−0.50 (−2.25,1.24)	− 0.29 (− 2.10,1.51)	−0.26 (− 2.00,1.49)	−0.69 (− 2.22,0.85)	−0.98 (− 2.20,0.25)	Vandetanib+Taxane (24.7%)
0.24 (− 1.62,2.11)	0.45 (− 1.47,2.37)	0.49 (− 1.37,2.35)	0.06 (− 1.61,1.73)	− 0.23 (− 1.62,1.16)	0.75 (− 1.11,2.60)	Vinflunine (61.1%)

SAE Severe adverse effect

^aThe SUCRA probabilities are performed in brackets